Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis
暂无分享,去创建一个
T. Nishino | T. Koji | K. Yanagihara | H. Mukae | S. Kohno | Y. Obata | T. Miyazaki | Y. Imamura | K. Izumikawa | Shinichi Abe | T. Takazono | Shintaro Shimamura | T. Saijo | Kazuko Yamamoto | Nobuyuki Ashizawa | N. Ashizawa | Tomomi Saijo
[1] Pengfei Guo,et al. A meta-analysis of randomized controlled trials , 2019, Medicine.
[2] C. Clancy,et al. Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences , 2018, Journal of fungi.
[3] Annalisa Capobianco,et al. The peritoneum: healing, immunity, and diseases , 2017, The Journal of pathology.
[4] M. H. Lee,et al. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model , 2017, Open Forum Infectious Diseases.
[5] Craig A. Poland,et al. Targeting lysyl oxidase reduces peritoneal fibrosis , 2017, PloS one.
[6] M. H. Lee,et al. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model , 2017, Antimicrobial Agents and Chemotherapy.
[7] Jung‐Chung Lin,et al. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials , 2017, PloS one.
[8] Wen-juan Wang,et al. Blocking TGF-β1 by P17 peptides attenuates gastric cancer cell induced peritoneal fibrosis and prevents peritoneal dissemination in vitro and in vivo. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[9] David W. Johnson,et al. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment , 2016, Peritoneal Dialysis International.
[10] S. Park,et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment , 2016, PloS one.
[11] T. Nishino,et al. Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation , 2016, Medical Molecular Morphology.
[12] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] D. Andes,et al. Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice , 2015, Antimicrobial Agents and Chemotherapy.
[14] M. Antonelli,et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality , 2015, Intensive Care Medicine.
[15] C. Clancy,et al. Abdominal Candidiasis Is a Hidden Reservoir of Echinocandin Resistance , 2014, Antimicrobial Agents and Chemotherapy.
[16] Ronald N. Jones,et al. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. , 2014, International journal of antimicrobial agents.
[17] M. Nagarkatti,et al. Role of cytokines as a double-edged sword in sepsis. , 2013, In vivo.
[18] A. Shorr,et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts , 2013, Intensive Care Medicine.
[19] Y. Tabata,et al. HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. , 2012, Acta biomaterialia.
[20] Amit X Garg,et al. Global trends in rates of peritoneal dialysis. , 2012, Journal of the American Society of Nephrology : JASN.
[21] David W. Johnson,et al. Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] O. Lortholary,et al. A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[23] Y. Tomino,et al. Quantitative evaluation and assessment of peritoneal morphologic changes in peritoneal dialysis patients. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] C. Venetis,et al. Prevention of intra-peritoneal adhesions in gynaecological surgery: theory and evidence. , 2010, Reproductive biomedicine online.
[25] O. Devuyst,et al. The pathophysiology of the peritoneal membrane. , 2010, Journal of the American Society of Nephrology : JASN.
[26] E. Anaissie,et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] M. Pfaller,et al. In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model , 2008, Antimicrobial Agents and Chemotherapy.
[28] A. Kimura,et al. In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine , 2008, Antimicrobial Agents and Chemotherapy.
[29] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[30] J. Keirns,et al. Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults , 2006, Antimicrobial Agents and Chemotherapy.
[31] H. Iwasaki,et al. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. , 2006, Translational research : the journal of laboratory and clinical medicine.
[32] J. Sobel,et al. Micafungin: a new echinocandin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Simona Gioberge,et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[34] S. Swan,et al. Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction , 2005, Journal of clinical pharmacology.
[35] T. Nishino,et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. , 2004, Kidney international.
[36] T. Koji,et al. Enhanced Expression of Heat Shock Protein 47 in Rat Model of Peritoneal Fibrosis , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[37] J. Jekel,et al. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] Geraint T. Williams,et al. Morphologic changes in the peritoneal membrane of patients with renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[39] Koji Kawabata,et al. In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi , 2000, Antimicrobial Agents and Chemotherapy.
[40] A. Kliger,et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] S. Davies,et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] T. Calandra,et al. Changes in the epidemiological landscape of invasive candidiasis , 2018, The Journal of antimicrobial chemotherapy.
[43] L. Miao,et al. A review of rodent models of peritoneal dialysis and its complications , 2014, International Urology and Nephrology.
[44] H. Flynn,et al. Update on the prevention and treatment of , 2014 .
[45] Francisco Ferreira,et al. Theory and Evidence , 2009 .